TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report sent to investors on Thursday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Up 3.0 %

TXMD stock opened at $1.37 on Thursday. TherapeuticsMD has a 1 year low of $1.15 and a 1 year high of $2.99. The stock’s 50 day moving average price is $1.56 and its 200 day moving average price is $1.76.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP raised its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the period. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent reporting period. 30.74% of the stock is owned by institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.